Traws Pharma, Inc. TRAW
0.24 USD +0.01 (+2.87%)
As ofNov 18, 2026, 1:17 PM EST
0.2319 Day range 0.2565
0.22 52-week range 3.23
- YTD
- -78.76%
- 1 year
- -88.73%
News
benzinga.com Traws Pharma Q3 EPS $(0.18) Beats $(0.20) Estimate Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 47.06 percent increase over losses of $(0.34)…
globenewswire.com Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights NEWTOWN, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies for…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma Inc. (NASDAQ:TRAW) announced final Phase 2a clinical data for its investigational oral COVID-19 therapy ratutrelvir alongside completed bridging and toxicology studies for its…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma reports positive Phase 2a ratutrelvir COVID-19 results and completes key tivoxavir marboxil flu studies ahead of FDA talks.benzinga.com Traws Pharma Reports Final Phase 2a COVID-19 Data, Advances Influenza Candidate Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID®, with no viral rebound through Day 28…
globenewswire.com Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID® Ratutrelvir , a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID ® , with no viral rebound through Day…benzinga.com Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments"…
